TrumpRx

News

Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.

Market Access

Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.

News

Merck KGaA has become the third drugmaker to reach a deal with the Trump administration to cut medicine costs, offering discounts on fertility drugs.

News

AstraZeneca has become the second pharma group to reach an agreement with the Trump administration on Most Favoured Nation (MFN) drug pricing.

News

Possible implications of TrumpRx, the federal direct-to-consumer sales channel, are starting to emerge ahead of its scheduled launch next year.

News

Donald Trump looks set to delay the introduction of his tariffs on pharma imports in order to negotiate more deals with drugmakers on drug pricing.